<DOC>
	<DOCNO>NCT00514709</DOCNO>
	<brief_summary>DTaP-HB-PRP~T combine vaccine develop order comply expand program immunization infancy , offer benefit reduce number injection , potentially increased acceptance . Primary Objectives : - To describe antibody persistence 12 18 month follow three-dose primary series vaccination either DTaP-HB-PRP~T Tritanrix-Hep B/Hib™ give 6 , 10 14 week age , one dose Hepatitis B ( Hep B ) vaccine give birth . - To describe effect booster dose DTaP-HB-PRP~T immunogenicity 12 18 month follow three-dose primary series vaccination either DTaP-HB-PRP~T Tritanrix HepB/Hib™ give 6 , 10 14 week age , one dose Hep B vaccine give birth . Secondary Objective : - To describe safety profile booster dose DTaP-HB-PRP~T vaccine administer concomitantly Oral Polio Vaccine ( OPV ) .</brief_summary>
	<brief_title>Immunogenicity Study Antibody Persistence Booster Effect DTaP-HB PRP~T Combined Vaccine Filipino Infants</brief_title>
	<detailed_description>This study assess immunogenicity reactogenicity investigational DTaP-HB-PRP~T combine vaccine give booster dose , concomitantly OPV , Filipino child previously prim 6 , 10 , 14 week investigational DTaP-HB-PRP~T combined vaccine Tritanrix-Hep B/Hib™ vaccine receive first dose Hep B vaccine ( Recomvax B™ ) birth previous study , AL201 ( NCT00348881 ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Toddler age 12 18 month age day inclusion ( range : 365 day 578 day age inclusive ) Participated AL201 study complete threedose primary series either DTaPHBPRP~T TritanrixHepB/Hib™ , OPV , 6 , 10 14 week age , receive hepatitis B vaccine birth Informed consent form sign one parent legal representative appropriate ( independent witness mandatory parent illiterate ) Able attend schedule visit comply trial procedure Participation another clinical trial 4 week precede trial vaccination Planned participation another clinical trial present trial period Congenital acquire immunodeficiency , immunosuppressive therapy longterm ( 2 week ) systemic corticosteroid therapy within precede 3 month Known systemic hypersensitivity vaccine component history lifethreatening reaction vaccine contain substance Chronic illness stage could interfere trial conduct completion Blood bloodderived product receive last 3 month Any vaccination 4 week precede trial vaccination Vaccination plan 4 week follow trial vaccination Febrile ( temperature ≥ 38.0°C ) acute illness day inclusion History document diphtheria , tetanus , pertussis , Haemophilus influenzae type b , hepatitis B poliomyelitis infection ( ) ( confirm either clinically , serologically , microbiologically ) Vaccination vaccine contain diphtheria , tetanus , pertussis , Haemophilus influenzae type b , hepatitis B poliovirus 3 type antigen , since end primary series Thrombocytopenia bleed disorder contraindicate IM vaccination Serious adverse event relate vaccination AL201 study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Hepatitis B Hansenula ( HB )</keyword>
	<keyword>Haemophilus influenzae type b</keyword>
</DOC>